A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE014 (NLD) · Dr. Moreau
consented 2022-07-08
Adverse events
Grade 2 Thrombocytopenia — outcome: UNKNOWN; onset 2022-10-29 (study day 98); relationship: N
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-10-31 (study day 100); relationship: N
Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2022-11-03 (study day 103); relationship: not assessed
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-11-10 (study day 110); relationship: Y
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-03-06 (study day 226); relationship: not assessed
Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2024-01-13 (study day 539); relationship: N
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-03-28 (study day 614); relationship: not assessed
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-04-12 (study day 629); relationship: N
Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2024-04-29 (study day 646); relationship: not assessed
Data queries
No data queries.